BioNTech SE - ADR Stock
BioNTech SE - ADR Stock price
Key metrics
| Market capitalization | $28.08b |
| Enterprise Value | $9.71b |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | 6.57 |
| EV/Sales (TTM) EV/Sales | 2.94 |
| P/S ratio (TTM) P/S ratio | 8.51 |
| P/B ratio (TTM) P/B ratio | 1.32 |
| Revenue growth (TTM) Revenue growth | -52.11% |
| Revenue (TTM) Revenue | $3.30b |
Is BioNTech SE - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.
BioNTech SE - ADR Stock Analysis
Analyst Opinions
22 Analysts have issued a BioNTech SE - ADR forecast:
Analyst Opinions
22 Analysts have issued a BioNTech SE - ADR forecast:
Financial data from BioNTech SE - ADR
| Sep '24 |
+/-
%
|
||
| Revenue | 3,300 3,300 |
52%
52%
|
|
| Gross Profit | 2,783 2,783 |
55%
55%
|
|
| EBITDA | -38 -38 |
101%
101%
|
EBIT (Operating Income) EBIT | -267 -267 |
107%
107%
|
| Net Profit | -502 -502 |
118%
118%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about BioNTech SE - ADR directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
BioNTech SE - ADR Stock News
Company Profile
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other diseases. The company is involved in developing FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 for prostate cancer; BNT113 that is in Phase I clinical trial to treat HPV+ head and neck cancers; BNT114, which is in Phase I clinical trial for triple negative breast cancer; and BNT115 and BNT116 to treat other cancers, including ovarian cancer. It also develops individualized neo-antigen specific immunotherapies, such as RO7198457, which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT152 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT212 for pancreatic and other cancers; next-generation checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I clinical trial to treat multiple solid tumors. Further, it develops MVT-5873, an IgG1 monoclonal antibody, which is in Phase I clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has a collaboration with Pfizer Inc. to develop vaccines for the coronavirus using its mRNA-based drug development platform; and development and commercialization collaboration with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to advance a vaccine candidate BNT162 for the prevention of COVID-19 infections. The company was founded in 2008 and is headquartered in Mainz, Germany.
| Head office | Germany |
| CEO | Ugur Sahin |
| Employees | 3,082 |
| Founded | 2008 |
| Website | www.biontech.de |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
